Loading…
← CockpitCompetitor Analysis › 688076.SS Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A688076.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese manufacturer of peptide active pharmaceutical ingredients used in diabetes, growth-hormone and other injectable drugs.

≈ A small Chinese peptide-API supplierMomentum strong 76
Mkt cap
$1.25B
US dollars, full cap
Free float
58%
of shares outstanding
$/day
$5.52M
20-day average traded
Fwd P/E
11.9×
forward earnings
ROIC−WACC
+4.0 pp
WACC 6.1%
Hurdle
-24 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥26.42
1D-2.9%
1W-6.2%
1M-5.7%
3M-5.7%
6M-15.6%
YTD-29.9%
1Y-30.6%
ATR %2.5%
52w lowhigh35.8% off high

What Sinopep-Allsino Bio Pharmaceutical does

Chinese manufacturer of peptide active pharmaceutical ingredients used in diabetes, growth-hormone and other injectable drugs.

In one line: A small Chinese peptide-API supplier.

Products and services

  • Peptide APIs
  • CDMO peptide manufacturing

Customers

  • Generic and innovator drug makers

Where it sits in the supply chain

  • Pharmaceuticals
  • Active ingredients
  • Peptide APIs

What could go right

  • GLP-1 and peptide-drug demand boom

What could go wrong

  • Customer concentration
  • Capacity competition from peers

Moat: narrow (process know-how, regulatory licence). Peptide synthesis and purification know-how plus regulatory filings are costly to replicate quickly.

Headquarters: China · Employees: 2,360

Named competitors

Sinopep-Allsino Bio Pharmaceutical at a glance

Size Sinopep-Allsino Bio Pharmaceutical (688076.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.25B, the 1784th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.42 on 18 Nov 2026.

Performance Over six months the shares fell 15.6%, against -17.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 14.1% over the last twelve months (peer median +1.8%); the operating margin is 18.6% (peer median -2.1%).

Valuation It trades at 11.9× forward earnings against a peer median of 21.3× (3rd cheapest of 10).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -24 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.0 points above its cost of capital (6.1% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026688076.SS 85Peer median 84
Six months, rebased to 100: Sinopep-Allsino Bio Pharmaceutical against the median of its 20 peers (local-currency closes).

Sinopep-Allsino Bio Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.16BCN¥1.94BCN¥1.62BCN¥1.03BCN¥642M
Revenue growth—+20%+57%+61%—
Gross profitCN¥1.42BCN¥1.14BCN¥1.04BCN¥575MCN¥330M
EBITDAn/aCN¥762MCN¥670MCN¥324MCN¥176M
Net incomeCN¥223MCN¥332MCN¥404MCN¥163MCN¥129M
Free cash flowCN¥156M-CN¥684M-CN¥689M-CN¥308M-CN¥408M
Capital expenditureCN¥856MCN¥1.37BCN¥1.09BCN¥661MCN¥438M
Total debtCN¥3.16BCN¥2.87BCN¥1.79BCN¥1.01BCN¥384M

Quarterly statements and history in the cockpit →

Sinopep-Allsino Bio Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%GHRS300204000950GPCRAMPHAVLN300026IDIA002332347850HROW2616LBRX3000062493OCULINVAMNKD688076.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Sinopep-Allsino Bio Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×200×400×300204000950AMPH300026002332HROW301263INVAMNKD688076.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sinopep-Allsino Bio Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%AMPH300026002332300006INVA688076.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sinopep-Allsino Bio Pharmaceutical is the large dot.

Sinopep-Allsino Bio Pharmaceutical competitors and peer comparison

Head to head with its named competitors (688076.SS vs BANB.SW vs PPGN.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sinopep-Allsino Bio Pharmaceutical 688076.SS$1.25B-16%+14%19%11.9×3.4%
Bachem BANB.SW$7.06B0%+5%19%32.4×n/a
PolyPeptide PPGN.SW$1.61B+7%+22%7%52.1×n/a

How Sinopep-Allsino Bio Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sinopep-Allsino Bio Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure688076.SSPeer medianRank in peer set
1-month return-5.7%-5.1%9th lowest of 20
6-month return-15.6%-17.3%10th highest of 20
Distance from 52-week high-35.8%-41.4%8th highest of 20
Revenue growth (TTM)+14.1%+1.8%5th highest of 16
Operating margin18.6%-2.1%3rd highest of 16
Forward P/E11.9×21.3×3rd cheapest of 10
Growth the price implies (Req g, 7 yrs)3.4%2.5%3rd most demanding of 6
Growth delivered (Del g)+27.9%-1.3%highest of 6
Hurdle (Req g minus delivered)-24.5 pp+1.0 ppleast demanding of 6
ROIC minus cost of capital+4.0 pp-9.0 pp2nd highest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%11.9×3.4%+27.9%
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%522.3×n/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%18.6×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%9.1×2.5%+15.5%
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%21.3×7.0%-5.3%
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%n/an/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%17.7×-0.4%-1.3%
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%n/an/an/a
Harrow HROWUnited States$1.21B+4%+21%1%26.8×n/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%60.7×n/an/a
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%n/an/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%n/a44.1%-13.2%
Mabwell (Shanghai) Bioscience 2493.HKHong Kong$1.20B-29%+21%-127%n/an/an/a
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%n/an/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%9.5×-17.2%+3.9%
MannKind MNKDUnited States$1.31B+25%+32%-2%174.4×n/an/a
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a

Questions

Who are Sinopep-Allsino Bio Pharmaceutical's main competitors?
Named competitors: Bachem (BANB.SW), PolyPeptide Group (PPGN.SW). The cockpit's measured peer set (industry) also includes GH Research (GHRS), Staidson (Beijing) Biopharmaceuticals (300204.SZ), C.Q. Pharmaceutical (000950.SZ), Structure Therapeutics, Inc. Sponsored ADR (GPCR), Amphastar Pharmaceuticals (AMPH), Avalyn Pharma (AVLN).
Is Sinopep-Allsino Bio Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 11.9× against a peer median of 21.3×, 3rd cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -24 pp: the price already allows for a slowdown.
How has Sinopep-Allsino Bio Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -15.6% against -17.3% for the median peer; over one year -30.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.